TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06608810
Drug: nerve block with 0.5% ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: General anesthesia tracheal intubation was used. Induction was performed with midazolam 0.05ml/kg, etomidate 0.3-0.4mg/kg, sufentanil 0.3μg/kg-0.4μg/kg, and rocuronium bromide 0.8mg/kg, and after sufficient oxygen and denitration, the tracheal tube was placed by visual laryngoscopy, and the position of the tube was determined by auscultation of the lungs to determine the position of the catheter, and the respiratory sounds of the sides were symmetrically clear, so that the catheter was fixed and mechanical ventilation was performed. Anesthesia was maintained with remifentanil 0.1～0.3μg/(kg-min), propofol 2\~4mg/(kg-h) rate microinfusion pump for continuous infusion. BIS was kept between 40\~60. Intraoperative rocuronium bromide was given intermittently to maintain muscle relaxation. Perioperative fluid replacement followed the (4:2:1) rule in all patients. For maintenance of hemodynamic stability, ephedrine or atropine was administered, at the anesthesiologist's discretion, if verified a
Study: NCT06607861
Drug: dexmedetomidine group
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: nebulization of 1 µg/kg dexmedetomidine diluted in 4 mL 0.9% saline twice daily
Study: NCT06607861
Drug: lidocaine group
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: bilateral nebulization (60 mg) using a mucosal atomization device twice daily
Study: NCT06439888
Drug: all-trans retinoic acid
Normalized name: all trans Retinoic acid
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: per os treatment, started from the same day as SBRT, during 3 successive days, every 3 weeks, for a maximum of 4 cycles
Study: NCT06301724
Drug: Lidocaine hydrochloride
Normalized name: Lidocaine Hydrochloride
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: the patients were provided with Stellate ganglion block , using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block . The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
Study: NCT00000344
Drug: Buprenorphine/naloxone
Normalized name: BUPRENORPHINE/NALOXONE
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT05363293
Drug: AL 001
Normalized name: Al
DrugBank: Latozinemab (DB16978)
Approvals — FDA: no, EMA: no, PMDA: no
Description: a crystal engineered lithium-salicylate-proline lithium delivery product
Study: NCT05894538
Drug: Ivermectin
Normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Each participant will receive a sufficient quantity of 7-mg tablets to be taken as directed based on their weight. The tablets are white, round, biconvex tablets with 123 over the scoring on one side. All packaging will be labeled to indicate that the product is for investigational use.
Study: NCT05249881
Drug: Semaglutide Pen Injector
Normalized name: semaglutide Pen Injector
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: All Diabetes mellitus type2 patients fulfilling the inclusion criteria, will receive 0.25mg Semaglutide injection per week and after two weeks dosage will be escalated to 0.5 mg/week for next 10 weeks.
Study: NCT06126952
Drug: Treatment A: Azelastine hydrochloride 0.15% nasal spray (Azelair)
DrugBank: Azelastine (DB00972)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 sprays per nostril of Azelastine 0.15% twice daily.~Total dose of active drug:~1644 mcg azelastine hydrochloride per day
Study: NCT06126952
Drug: Treatment C: Ryaltris (Active Control) - mometasone furoate monohydrate and olopatadine hydrochloride nasal spray
DrugBank: Mometasone (DB00764)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 sprays per nostril of Ryaltris twice daily.~Total dose of active drug:~200 mcg mometasone furoate and 4800 mcg olopatadine per day
Study: NCT05256342
Drug: Duloxetine 60mg
Normalized name: DULOXETINE 60MG CAP,SPRINKLE,EC
DrugBank: Duloxetine (DB00476)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eight weeks treatment, one pill daily.~1st week 30mg; weeks 2-7th -- 60 mg daily.
Study: NCT05256342
Drug: omeprazol
Normalized name: Omeprazol
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 mg daily; will be taken with Etoricoxib from the second week of treatment
Study: NCT05908526
Drug: suvorexant (or placebo)
Normalized name: Suvorexant
DrugBank: Suvorexant (DB09034)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: FDA approved which is an orexin receptor antagonist indicated for the treatment of insomnia, characterized by difficulties with sleep onset and/or sleep maintenance.
Study: NCT06044805
Drug: Chloroquine
Normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Total of 25mg base per kg over 3 days (10 mg base/kg on Days 0 and 1, 5 mg base/kg on Day 2)
Study: NCT06044805
Drug: Primaquine
Normalized name: Primaquine
DrugBank: Primaquine (DB01087)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Primaquine: 7.5 mg base tablet. Medication given as 0.25mg/kg daily for 14 days.
Study: NCT05941338
Drug: Tirelizumab ,+Carboplatin+albumin-bound paclitaxel
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sintilimab (IV), dose= 200mg , day=1 , cycle length: 21 days. Carboplatin (IV), dose=300mg/m2, day= 1, cycle length: 21 days. albumin-bound paclitaxel (IV), dose=260mg/m2, day= 1, cycle length: 21 days. Intervention: Drug: Sintilimab , Carboplatin, albumin-bound paclitaxel
Study: NCT06455410
Drug: Adebrelimab
Normalized name: Adebrelimab
DrugBank: Adebrelimab (DB16412)
Approvals — FDA: no, EMA: no, PMDA: no
Description: a PD-L1 inhibitor
Study: NCT04819438
Drug: Riluzole 50 mg Oral Film
Normalized name: riluzole 50 MG Oral Film
DrugBank: Riluzole (DB00740)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Before each administration, the subjects will drink 20 mL of still mineral water in order to wet their mouth. Afterwards, using gloves, the investigator or deputy will take the orodispersible film (32.0x22.0 mm) out of the provided pouch and place the product directly on the top surface (dorsal aspect) of the subjects' tongue.
Study: NCT04819438
Drug: Rilutek 50Mg Tablet
Normalized name: Rilutek 50mg Tablet
DrugBank: Riluzole (DB00740)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One film-coated tablet will be swallowed (without chewing) with 150 mL of still mineral water.
Study: NCT06099418
Drug: Atezolizumab Injection [Tecentriq]
Normalized name: atezolizumab Injection [Tecentriq]
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous (IV) infusions of atezolizumab (saline solution) every 3 weeks.
Study: NCT05422781
Drug: ITI-3000
Normalized name: Arthur Itis
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ITI-3000 is a DNA vaccine (L-H LT S220A) which contains sequences for both LAMP1 and LTS220A, the truncated form of the LT antigen of MCPyV with a detoxifying serine to alanine mutation at position 220
Study: NCT05523596
Drug: ICM20
Normalized name: Icodextrin
DrugBank: Icodextrin (DB00702)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: small molecules
Study: NCT05523596
Drug: Benznidazole
Normalized name: benznidazole
DrugBank: Benznidazole (DB11989)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: small molecule
Study: NCT00481559
Drug: Voraxaze (glucarpidase)
Normalized name: Voraxaze
DrugBank: Glucarpidase (DB08898)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 50 Units/kg in a bolus intravenous injection over 5 minutes
Study: NCT05816642
Drug: sunitinib or pazopanib
DrugBank: Sunitinib (DB01268)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Single targeted therapy
Study: NCT05816642
Drug: PD-1 inhibitor combined with axitinib
Normalized name: Anti-pd-1 checkpoint inhibitor pf-06801591
DrugBank: Axitinib (DB06626)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: targeted therapy combined with immunotherapy
Study: NCT05882864
Drug: 6-Gingerol
Normalized name: 6-Gingerol
DrugBank: Gingerol (DB19255)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-gingerol gel will be applied locally to the participants suffering from oral lichen planus
Study: NCT05882864
Drug: Triamcinolone Acetonide 0.1% Oromucosal Paste
Normalized name: Triamcinolone Acetonide 0.1% Oromucosal Paste
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triamcinolone Acetonide 0.1% gel will be applied locally to the participants suffering from oral lichen planus
Study: NCT05940545
Drug: Favipiravir
Normalized name: favipiravir
DrugBank: Favipiravir (DB12466)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Small molecule antiviral
Study: NCT05940545
Drug: Ribavirin
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Small molecule antiviral
Study: NCT06434662
Drug: mitoxantrone hydrochloride liposome
Normalized name: Mitoxantrone Hydrochloride
DrugBank: Mitoxantrone (DB01204)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mitoxantrone hydrochloride liposome (24 mg/m\^2) on day 1, every 4 weeks
Study: NCT06434662
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cytarabine (1.0 g/m\^2, q12h ) on day 1,3,5, every 4 weeks
Study: NCT06434662
Drug: Venetoclax
Normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Venetoclax 100 mg on day 2，200 mg on day 3，400 mg on day 4-10, every 4 weeks
Study: NCT06067048
Drug: Zanubrutinib Oral Capsule
Normalized name: zanubrutinib Oral Capsule
DrugBank: Rutin (DB01698)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 36 cycles (1 cycle is 28 days)
Study: NCT04698785
Drug: Treatment by regorafenib and best supportive care
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Treatment for 13 cycles (12 months) maximum.~During each cycle :~* patients ≥ 16 years old and patients \<16 old with Body Surface Area (BSA) ≥ 1,70 m2 will take 3 tablets, once a day, corresponding to a total of 120 mg Regorafenib, during 21 days, followed by 7 days without treatment.~* patients \< 16 years old with a 1,30 m2 ≤ BSA ≥ 1,70 m2 will take 2 tablets, once a day, corresponding to a total of 80 mg Regorafenib, during 21 days, followed by 7 days without treatment
Study: NCT05569538
Drug: Bomedemstat
Normalized name: Bomedemstat
DrugBank: Bomedemstat (DB17234)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bomedemstat will be self-administered orally once daily. In both cohorts, the dose of bomedemstat will be adjusted in each patient based on titration of the patient's platelet count to the target range. Ruxolitinib will be self-administered orally. Both medications will continue uninterrupted in 28-day cycles. Subjects will continue combination treatment through the Initial Treatment Period (first 6 cycles), which includes a Qualification Assessment. Those deriving clinical benefit in the opinion of the treating physician may continue receiving combination treatment in the Additional Treatment Period (6 cycles). Qualification Assessments will be performed at the end of each Additional Treatment Period, which is iterative, and may repeat for as long as clinical benefit is sustained, at the discretion of the treating physician.
Study: NCT05192629
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Premedication by intranasal dexmedetomidine
Study: NCT05192629
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Premedication by intranasal midazolam
Study: NCT06607367
Drug: Ruxolitinib (JAKAVI®)
DrugBank: Ruxolitinib (DB08877)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Initial starting dose will be 10mg BD
Study: NCT06607367
Drug: Eltrombopag (Revolade®)
DrugBank: Eltrombopag (DB06210)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Initial starting dose will be 50mg daily
Study: NCT06609226
Drug: Etavopivat A
Normalized name: Etavopivat
DrugBank: Etavopivat (DB18176)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive an oral dose of Etavopivat A.
Study: NCT06609226
Drug: Etavopivat B
Normalized name: Etavopivat
DrugBank: Etavopivat (DB18176)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive an oral dose of Etavopivat B.
Study: NCT06607926
Drug: Tislelizumab
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200mg, IV, d1 of each 21-d cycle, four cycles
Study: NCT06607926
Drug: Platinum-doublet chemotherapy
Normalized name: platinum
DrugBank: Platinum (DB12257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy regimen: (1) for squamous cell carcinoma: cisplatin/carboplatin + paclitaxel; and (2) for non-squamous cell carcinoma: cisplatin/carboplatin + pemetrexed.
Study: NCT05184101
Drug: Unfractionated Heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Heparin sodium will be administered as a nebulised aerosol dose of 25,000 IU heparin three times a day (TDS) via an Aerogen Solo (Aerogen, Ireland) vibrating mesh aerosol drug nebulizer.
Study: NCT06194955
Drug: GLP-1
Normalized name: rGLP-1
DrugBank: rGLP-1 (DB05433)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion
Study: NCT06194955
Drug: GLP-2
Normalized name: (Gly2)GLP-2
DrugBank: Teduglutide (DB08900)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infusion
Study: NCT06468527
Drug: Diponecaftor
Normalized name: Dirocaftor
DrugBank: Dirocaftor (DB16143)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diponecaftor is a triple combination of DIR/POS/NES. The combination therapy will be administered orally during 8 weeks. The daily dose contains:~* DIR 300 mg/day~* POS 600 mg/day~* NES 10 mg/day
Study: NCT05517213
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Chemotherapy combined with rhG-CSF is widely used in autologous hematopoietic stem cell mobilization programs. For patients who do not meet the criteria of stem cell collection, they can be mobilized again after 1 month of rest. Chemotherapy +rhG-CSF mobilization or rhG-CSF+ ploxafo steady-state mobilization can be used.
Study: NCT04644796
Drug: Liposomal bupivacaine
Normalized name: bupivacaine liposome
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients included in the treatment group will have their incisional site infused, targeting the paraspinal muscles with liposomal bupivacaine at the end of their surgery.
Study: NCT04782245
Drug: Dapagliflozin 10mg
Normalized name: DAPAGLIFLOZIN 10MG TAB
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The intervention group will receive, during 6 months, dapagliflozin per oral route at a dose of 10 mg once daily in addition to the optimal medical management based on current heart failure practice guidelines.
Study: NCT06086444
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic Acid (10mg/kg), diluted in 100 ccs of normal saline. Administered intravenously at least 10 minutes before skin incision.
Study: NCT04862949
Drug: Atezolizumab plus bevacizumab
Normalized name: Atezolizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Atezolizumab plus bevacizumab
Study: NCT05685732
Drug: Serdexmethylphenidate (SDX) and dexmethylphenidate (d-MPH)
Normalized name: dexmethylphenidate and serdexmethylphenidate
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Serdexmethylphenidate (SDX) and dexmethylphenidate (d-MPH)
Study: NCT04659928
Drug: Hydrogen Peroxide
Normalized name: Hydrogen Peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will be given 1.5 % Oral Solution of hydrogen peroxide mouth rinse
Study: NCT04855955
Drug: Adipose-Derived Mesenchymal Stem Cells
Normalized name: Adipose-Derived Mesenchymal Stem Cells: Autologous or Allogeneic Origins
DrugBank: Adipose-Derived Mesenchymal Stem Cells: Autologous or Allogeneic Origins (DB15729)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04947631
Drug: DKF-313
Normalized name: DKFZ-PSMA-11 Ga-68
DrugBank: Gallium Ga-68 gozetotide (DB16019)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of dutasteride 0.5 mg and tadalafil 5 mg once daily for 48 weeks
Study: NCT04947631
Drug: Dutasteride
Normalized name: Dutasteride
DrugBank: Dutasteride (DB01126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dutasteride 0.5 mg once daily for 48 weeks
Study: NCT04947631
Drug: Tadalafil
Normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tadalafil 5 mg once daily for 48 weeks
Study: NCT04947631
Drug: Dutasteride placebo
Normalized name: Dutasteride
DrugBank: Dutasteride (DB01126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Once daily for 48 weeks
Study: NCT04947631
Drug: Tadalafil placebo
DrugBank: Tadalafil (DB00820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Once daily for 48 weeks
Study: NCT06119880
Drug: Pancreatin Enteric-coated Capsules
Normalized name: Pancreatin
DrugBank: Pancrelipase (DB00085)
Approvals — FDA: no, EMA: no, PMDA: no
Description: pancreatic enzyme replacement therapy
Study: NCT04580277
Drug: Tofacitinib 10 mg
Normalized name: tofacitinib 10 MG
DrugBank: Tofacitinib (DB08895)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subjects in this arm will receive tofactinib 10 mg twice daily for 8 weeks
Study: NCT04932213
Drug: Tropicamide Ophthalmic
Normalized name: tropicamide ophthalmic
DrugBank: Tropicamide (DB00809)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tropicamide eye drops are used for dilating pupils (mydriasis) to do comprehensive fundus examination.
Study: NCT04975958
Drug: Atezolizumab 1200 mg in 20 ML Injection
Normalized name: atezolizumab 1200 MG in 20 ML Injection
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: infusion
Study: NCT05254405
Drug: Brexanolone Injection [Zulresso]
Normalized name: brexanolone Injection [Zulresso]
DrugBank: Brexanolone (DB11859)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous infusion of brexanolone over 60 hours titrated to a maximal dose of 90 mcg/kg/hr.
Study: NCT05296460
Drug: Dapsone gel
Normalized name: Dapsone
DrugBank: Dapsone (DB00250)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The patients will use topical dapsone gel 7.5% once daily on left side of face ,The patients will use TCA20% peeling as a peeling session every 2 weeks (6 sessions) on right side of face
Study: NCT06605911
Drug: topical triamcinolone acetonide
Normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ten patients with OLP were received topical triamcinolone acetonide four times per day for six weeks
Study: NCT06605911
Drug: Topical Curcumin
DrugBank: Cumin (DB10864)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ten patients with OLP received topical curcumin four times per day for six weeks.
Study: NCT06605911
Drug: topical triamcinolone acetonide combiend with topical curcumin
Normalized name: triamcinolone acetonide Topical Ointment
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ten patients with OLP received a combination of topical triamcinolone acetonide and topical curcumin four times per day for six weeks.
Study: NCT04077866
Drug: Temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Temozolomide is an FDA-approved drug that is given to patients
Study: NCT05176002
Drug: Camrelizumab
Normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant Camrelizumab combined with radiotherapy
Study: NCT05628506
Drug: Potassium iodide
Normalized name: Potassium Iodide
DrugBank: Potassium Iodide (DB06715)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive a single oral administration of a pharmacological dose (97.5 mg) of potassium iodide 20±4 hours before surgery.
Study: NCT04924036
Drug: glycopyrronium cloths
DrugBank: Glycopyrronium (DB00986)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qbrexza is an anticholinergic indicated for topical treatment of axillary hyperhidrosis in adults and pediatric patients 9 years of age and older
Study: NCT06225024
Drug: BoNT A
Normalized name: BoNT/A-DS
DrugBank: LetibotulinumtoxinA (DB16820)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BoNT-A is widely recognized as the benchmark for enhancing the effectiveness of spasticity management
Study: NCT05180318
Drug: Esketamine Hydrochloride 28 Mg in 0.2 mL NASAL SOLUTION [Spravato]
Normalized name: ESKETAMINE HYDROCHLORIDE 28 mg in 0.2 mL NASAL SOLUTION [Spravato]
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Esketamine (0.25 mg/kg) will be given intravenously 24-36 hours before surgery (infusion time: 40 min) and immediately after surgery (infusion time: 40 min).
Study: NCT05105841
Drug: Venetoclax
Normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral Tablet
Study: NCT05105841
Drug: Ibrutinib
Normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral Capsule
Study: NCT05105841
Drug: Obinutuzumab
Normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous (IV) Infusion
Study: NCT05933642
Drug: Aminophylline
Normalized name: Aminophylline
DrugBank: Aminophylline (DB01223)
Approvals — FDA: no, EMA: no, PMDA: no
Description: aminophylline 150mg
Study: NCT05933642
Drug: Frusemide
Normalized name: Frusemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: frusemide 120mg
Study: NCT05244460
Drug: Droperidol Injectable Product
Normalized name: droperidol Injectable Product
DrugBank: Droperidol (DB00450)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment
Study: NCT05244460
Drug: Diphenhydramine
Normalized name: Diphenhydramine
DrugBank: Diphenhydramine (DB01075)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment
Study: NCT06114758
Drug: Cytotec 200Mcg Tablet
Normalized name: Cytotec 200mcg Tablet
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: the admistiration of 400 Mcg rectal cytotec while starting the surgery, just before the patient is covered
Study: NCT06114758
Drug: Transamine
Normalized name: Transamine
DrugBank: Tranylcypromine (DB00752)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 gram intravenous slow infusion intraoperatively as we start the laparatomy
Study: NCT05450887
Drug: UDCA
Normalized name: UDCA
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: UDCA：13\~15 mg/kg/day